1. Repository of OAI
Ελληνικά   English  
Saved Searches

Discover

Search


Current filters:



Clear current filters  or Add more filters

View Option


Results 11-20 of 21 (Search time: 0.005 seconds).

  Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group (Journal article)

  Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study (Journal article)

  Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study (Journal article)

  Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer (Journal article)

  Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group (Journal article)

  Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer (Journal article)

  Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study (Journal article)

  Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study (Journal article)

  Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study (Journal article)